Archer Capital
Archer cuts fees on buyout fund – report
Archer Capital has reportedly lowered the management fee on its A$1.5 billion ($1.34 billion) fifth fund by 20%.
Silver lining: Investing in Asia's elderly
An established investment trend in developed markets, private equity players in emerging Asia are considering how they can best meet the needs of the region’s aging population
Archer’s Brownes buys Ravenhill Dairy assets
Archer Capital-owned Brownes has agreed to buy Ravenhill Dairy’s brand, processing assets and milk supply as it bids to double turnover to A$400 million over the next five years and steal a march on Western Australia rivals Harvey Fresh and Lion.
Archer-owned Australian Aged Care buys Lend Lease's care unit
Australian Aged Care Partners, an Archer Capital portfolio company, has agreed to buy property group Lend Lease's aged care unit for A$270 million ($276 million). The transaction is expected to be completed by the end of March 2013.
Going walkabout: Australian outbound investment
Taking portfolio companies from Australia into Asia represents a major opportunity for private equity. Pan-regional funds see it as a key part of their strategy, but can domestic players join the party?
Australian GPs see strong investment climate, challenges for exits
Australia’s private equity investment environment is at its strongest in five years but this is tempered by managers facing more challenges selling portfolio companies, according to Anthony Kerwick, managing director at Pacific Equity Partners (PEP).
AVCJ Australia webinar takes place Thursday
The opportunities and challenges facing Australian private equity will be discussed by a panel of industry experts at an AVCJ webinar on February 21. It begins at 11 a.m. (2 p.m. AEST) and will last for approximately 45 minutes. Audience members will...
Trafigura subsidiary buys Ausfuel from Archer Capital
Archer Capital has exited Ausfuel to Puma Energy, a subsidiary of Trafigura, for a reported cash sum of $650 million. The Australian GP acquired a majority stake in the company from CHAMP Ventures in 2010, paying around A$120 million ($125 million).
Blackstone appoints ex-Archer partner as Australia senior advisor
The Blackstone Group has appointed James Carnegie as a senior advisor based in Sydney, where he will focus primarily on developing the firm’s private equity activity in Australia. He previously spent seven years at Archer Capital, leaving the local...
Archer Growth prepares for Cura Day exit – report
Archer Capital Growth is reportedly preparing to exit Cura Day Hospitals Group. The Australian GP helped found the company in 2008, having teamed up with a group of doctors and medical specialists who manage and work at its nationwide network of day hospitals.
Oz law firm appoints PE expert
Australian law firm Corrs Chambers Westgarth has hired private equity lawyer Philip Kapp to be a senior partner. Kapp claims to have been involved in almost every major Australian PE deal since 2000.
Offshore investors: Leap into the unknown
With commitments from domestic LPs easing off, Australian, Japanese and Korean GPs are looking to raise capital from overseas investors. They are entering new territory and some are better prepared than others
Archer Growth invests in Best Friends Pet Supercentre
Archer Capital Growth Funds, the Australian GP’s lower mid-market unit, has set up a partnership with Best Friends Pet Supercentre and plans to expand the chain to 44 outlets. The company currently operates 11 supercenters that sell pet products and...
VIDEO: Archer Capital's Greg Minton
Australian fund managers need to go offshore to raise capital – but only if they are targeting large funds, says Greg Minton, managing director at Archer Capital. “In fund IV we got about A$740 million from the domestic market and about the same again...
Australia’s lower mid-market retains its appeal
Successful fundraises by CHAMP Ventures and Archer Capital Growth Funds suggest that foreign LPs are willing to fill the gap left by Australian institutions. Performance and consistency remain the key factors
Archer, CHAMP among bidders for CVC’s Mantra - report
Archer Capital and CHAMP Private Equity are reportedly among the PE firms bidding for Australia’s Mantra Group, which CVC Asia Pacific put up for auction in March.
TPG rivals mull bids for Billabong – report
The Blackstone Group and KKR are reportedly considering bids for Billabong after the Australian surfwear company rejected TPG Capital’s A$841 million ($904 million) offer but said it was willing to engage with any party that make an attractive proposal.
Q&A: Archer Capital's Peter Wiggs
At a time when Australian GPs are seeing changes in everything from LP bases to exit options, Peter Wiggs, managing director of Archer Capital, says that a consistent investment strategy can pay dividends
Australian fundraisers feel the strain
Are changes in superannuation laws the cause or the scapegoat? Either way, Australia’s fundraising landscape is undergoing substantial change. Local GPs must choose between going offshore or going out of business
Archer secures $1.5b for fifth fund
Projections for Archer Capital's fifth fund continued to increase even as the capital-raising environment in Australia got tougher. A target of A$1.2 billion ($1.2 billion) soon became A$1.4 billion and finally A$1.5 billion, which is where it closed...
Archer Capital closes fifth fund at $1.5b
Australia’s Archer Capital has closed its fifth fund at A$1.5 billion ($1.52 billion), having spent less than four months in the market. The vehicle, which counts domestic and international institutions among its investors, was significantly oversubscribed.
Private Equity Professional of the Year – Peter Wiggs
“It's been quite a year,” Peter Wiggs reflected as he collected the prize for Private Equity Professional of the Year at the 2011 Asian Private Equity & Venture Capital Awards.
Archer, Ironbridge achieve iNova exit
It may have taken longer than expected, but Archer Capital and Ironbridge Capital have finally exited Australian portfolio company iNova Pharmaceuticals to a Canadian trade buyer two years after launching an auction for the company. A healthy return on...
Archer, Ironbridge exit iNova Pharmaceuticals for $690m
Archer Capital and Ironbridge Capital have exited iNova Pharmaceuticals to Canada’s Valeant Pharmaceuticals in a deal worth up to A$700 million ($690 million). Valeant will pay A$625 million up front plus a further A$75 million based on the success...